Search
R-Biopharm has successfully completed a Series A+ funding round worth tens of millions of yuan to propel forward the clinical development and market introduction of its groundbreaking PCV24 vaccine. This vaccine, the world's pioneering non-toxic dual-vector 24-valent pneumococcal polysaccharide conjugate vaccine, has garnered clinical approval for use across all age groups. Notably, the adult indication has advanced through Phase II trials and is poised to enter Phase III, while preliminary data from Phase I trials for the infant indication have already been secured. Boasting independent intellectual property rights, PCV24's innovative non-toxic dual-vector design elevates both the safety and immune efficacy of the vaccine, offering an unparalleled comprehensive solution for the prevention of pneumococcal diseases.
-
C114 Communication Network -
Communication Home
